替代复苏策略、宿主反应与损伤生物标志物及脓毒症休克结局的关系:基于早期脓毒症休克方案化治疗研究的分析
该研究为早期脓毒症休克方案化治疗试验的二次分析,纳入美国31家医院628例脓毒症休克患者,比较两种复苏方案与常规治疗。在0、6、24、72小时检测炎症、凝血、氧化应激和组织缺氧四类生物标志物。所有基线生物标志物浓度越高,90天死亡风险越高;但治疗分组未显著影响生物标志物轨迹。基线白介素-6及白介素-6×白介素-10最低四分位患者接受方案化复苏的死亡率更低(OR 0.32),提示治疗效应存在异质性。
要点
- 脓毒症休克患者基线炎症、凝血、氧化应激和组织缺氧生物标志物浓度越高,90天死亡风险越高。
- 两种方案化复苏与常规治疗相比,未显著改变72小时内生物标志物轨迹。
- 基线白介素-6最低四分位患者接受方案化复苏的90天死亡OR为0.32(95%CI 0.13-0.75;P=0.01)。
- 基线白介素-6×白介素-10最低四分位患者接受方案化复苏的90天死亡OR为0.32(95%CI 0.14-0.73;P=0.01)。
- 方案化复苏在基线炎症标志物较低患者中似乎更优,但机制不明。
适用人群与场景
- 美国31家医院收治的脓毒症休克患者628例。
- 研究为早期脓毒症休克方案化治疗试验的二次分析。
处置流程与药物剂量
- 两种复苏方案与常规治疗进行比较;原文未给出具体方案药物、剂量、给药途径、频次或目标值。
研究设计与关键结果
- 研究类型为大型随机临床试验的二次分析,纳入628例脓毒症休克患者,来自美国31家医院。
- 干预为两种复苏方案与常规治疗对比;在0、6、24、72小时检测炎症(肿瘤坏死因子、白介素-6、白介素-10)、凝血(D-二聚体、凝血酶-抗凝血酶复合物)、氧化应激(尿异前列腺素)和组织缺氧(乳酸)生物标志物。
- 所有基线生物标志物浓度越高,90天死亡风险越高。
- 治疗分组对后续生物标志物轨迹无显著影响。
- 基线白介素-6最低四分位患者接受方案化复苏的90天死亡OR为0.32(95%CI 0.13-0.75;P=0.01);基线白介素-6×白介素-10最低四分位患者OR为0.32(95%CI 0.14-0.73;P=0.01),提示治疗效应异质性。
证据类型、等级与局限
- 证据类型为随机临床试验的二次分析;原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论提示方案化复苏在基线炎症标志物较低患者中似乎更优,但机制不明;作者认为该效应机制不清。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: The Protocol-based Care for Early Septic Shock trial found no differences across alternative resuscitation strategies in all-cause mortality. A separate aim was to determine whether differences in resuscitation strategies affected trajectories of biomarkers of key pathways associated with downstream clinical outcomes of sepsis and whether there were differences in survival across treatment arms for patients with different baseline biomarker profiles.
DESIGN: Secondary analysis of a large randomized clinical trial.
SETTING: Thirty-one U.S. hospitals.
PATIENTS: Six hundred twenty-eight patients with septic shock.
INTERVENTIONS: Two resuscitation protocols versus usual care.
MEASUREMENTS AND MAIN RESULTS: We measured a panel of biomarkers representing four pathophysiologic domains: "inflammation" (tumor necrosis factor, interleukin-6, and -10); "coagulation" (D-dimers, thrombin-antithrombin complex); "oxidative stress" (urine isoprostane); and "tissue hypoxia" (lactate) at 0, 6, 24, and 72 hours after treatment. We analyzed whether alternative resuscitation strategies affected biomarker trajectories over 72 hours and whether effects on 90-day hospital mortality varied by baseline (time 0) biomarker profiles-both using regression models with interaction terms for treatment arms. For all baseline biomarkers, higher concentrations were associated with increased risk of death by 90 days. However, there was no significant effect of treatment assignment on subsequent biomarker trajectories. We did find evidence for heterogeneity of treatment effect of protocol-based care on mortality for patients with different baseline [interleukin-6] and [interleukin-6] × [interleukin-10] profiles, whereas patients with the lowest quartiles fared better with protocol-based care (odds ratios, 0.32 [0.13-075]; p = 0.01 and 0.32 [0.14-0.73]; p = 0.01, respectively).
CONCLUSIONS: In patients with septic shock, alterations in inflammation, coagulation, oxidative stress, and tissue hypoxia are common and associated with adverse outcomes but are not influenced by protocol-based resuscitation compared with usual care. However, contrary to expectation, protocol-based resuscitation appeared to be superior in patients with lower concentrations of inflammatory biomarkers. The mechanisms responsible for this effect are unclear.
参考来源
- Kellum JA, Pike F, Yealy DM, et al. Relationship Between Alternative Resuscitation Strategies, Host Response and Injury Biomarkers, and Outcome in Septic Shock: Analysis of the Protocol-Based Care for Early Septic Shock Study. Crit Care Med. 2017. PMID: 28079606. doi:10.1097/CCM.0000000000002206
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。